Screen capture via Acadia's website.
Acadia And Proteostasis: Risk On?
Since June of 2017, I have presented my system's top 10 names to my Marketplace subscribers each week. So far, we have full six-month performance numbers for 106 of those top names cohorts, and they have outperformed the SPDR S&P 500 ETF (SPY) by 2.4% annualized on average. Last month, I described changes we made in our ranking process (Finding Alpha In Security Selection). Those changes essentially prioritized less risky names. So why did two biopharmaceutical companies, Acadia (ACAD